Geographic Atrophy

Latest News

OCT device and retinal image Image credit: AdobeStock/meenon
New study examines soft drusen regression without atrophy and drusen ooze

September 11th 2025

Researchers conducted this study to determine how often and why spontaneous soft drusen regresses without atrophy in patients who had intermediate or atrophic age-related macular degeneration.

Physician conducting eye exam with fundus camera Image credit: AdobeStock/MedicalWorks
Case report: Gyrate atrophy of the choroid and retina

July 29th 2025

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Image credit: ©Monster Ztudio—stock.adobe.com
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD

July 8th 2025

Genetic link found between instant coffee consumption and dry AMD. - Image credit: ©Avocado_studio—stock.adobe.com
Genetic link found between instant coffee consumption and dry AMD

June 19th 2025

Person filling out scorecard on clipboard. Image credit: AdobeStock/RonAlvey
New national scorecard exposes insurance coverage disparities for vision-threatening disease treatments

May 26th 2025

More News

Apellis Pharmaceuticals announced Tuesday top-line, 24-month data of the phase 3 DERBY and OAKS studies analyzing intravitreal pegcetacoplan for geography atrophy (GA) secondary to age-related macular degeneration (AMD).

Apellis releases 24-month results of phase 3 studies for GA treatment

Alex Delaney-Gesing, Senior Editor
August 24th 2022

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.

Apellis receives FDA acceptance, priority review of NDA for GA treatment

Apellis receives FDA acceptance, priority review of NDA for GA treatment

Alex Delaney-Gesing, Senior Editor
July 19th 2022

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.

Imaging technology helps in scanning for retinal diseases

Imaging technology helps in scanning for retinal diseases

Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO
July 15th 2022

Advancements enable better diagnosis, treatment of patients.

Apellis submits NDA for pegcetacoplan to treat GA

Apellis submits NDA to FDA for geographic atrophy treatment

Alex Delaney-Gesing, Senior Editor
June 1st 2022

A decision by the FDA is expected in August 2022.

What’s hot (and not) in retinal news

What’s hot (and not) in retinal news

Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO
May 12th 2022

A look at the latest developments in retinal disease, including clinical trials and advanced therapies.

Apellis releases 18-month results from phase 3 studies of pegcetacoplan for GA

Apellis releases 18-month results from phase 3 studies of pegcetacoplan for GA

Alex Delaney-Gesing, Senior Editor
May 5th 2022

New detailed, longer-term findings were presented at the 2022 ARVO meeting.

<1234
© 2025 MJH Life Sciences

All rights reserved.